Obesity Medicine

A novel study strongly suggests that pre-pregnancy obesity rather than associated adverse pregnancy outcomes is the "culprit" in postpartum heart disease.

Semaglutide treatment reduced weight and was associated with greater, more consistent improvements in HFpEF than other recently studied drug classes.

Your daily dose of the clinical news you may have missed.

Sandra Christensen, MSN, ARNP, gives her top strategies on patient selection for treatment with antiobesity medications and how to choose the right drugs for patients.

Your daily dose of the clinical news you may have missed.

Waist-to-hip ratio was more powerfully and consistently associated with risk of all-cause mortality than BMI or FMI, but can it replace BMI as a clinical indicator?

The new app is designed to help persons with diabetes understand how food and activity impact blood glucose levels and to revise behavior accordingly.

An intensive parent-support early childhood obesity intervention program led to better weight status outcomes in the long-term compared to standard therapy, report study authors.

Obesity specialist Sandra Christensen, MSN, ARNP, compares the benefits and drawbacks among older antiobesity drugs and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.

Obesity specialist Sandra Christensen, MSN, ARNP, details the differences between older antiobesity medications and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.

The selective aldosterone synthase inhibitor will move into late stage clinical trials, a nod to the potential for a first-in-class agent targeting aldosterone.

The class of GLP-1 receptor agonists and similar agents, originally approved to treat type 2 diabetes, also reduce body weight and reduce CVD risk; what's next?

Your daily dose of clinical news you may have missed.

Elevated inflammation, rather than depression, may drive poor weight loss outcomes in patients with obesity following bariatric surgery, suggest authors of new study.

Your daily dose of clinical news you may have missed.

Your daily dose of clinical news you may have missed.

Atrial fibrillation prevalence is rising across socioeconomic strata globally, the new analysis finds, with effects of BMI, ETOH, and sedentary behavior shifting as key drivers.

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Three key drivers of the perennial increase in OA prevalence are population growth, aging, and obesity, said authors of the analysis for the Global Burden of Disease study.

A daily dose of clinical news on Patient Care you may have missed.

ESC Congress 2023. The results of STEP-HFpEF could "change the nature of the conversation about the role of obesity in HFpEF," said PI Mikhail Kosiborod, MD.

Before creating a nutrition plan for patients with obesity, clinicians should first understand their eating patterns, says one obesity expert.

More than 90 million adults in the US with overweight/obesity are candidates for weight loss treatment with semaglutide 2.4 mg, according to a new study.

A daily dose of clinical news on Patient Care you may have missed.

Dr Alina Elperin details which medications primary care clinicians should be prepared to prescribe patients with obesity to help prevent cardiovascular disease, here.